
Over 25,000 of TheraCell’s licensed demineralized bone fiber products have been delivered by its licensee partners, to date. These partners have notched steady double-digit quarter over quarter growth, now representing an annual end customer sales rate approaching $30 million.
Licensees of the base fiber technology include AlloSource, which produces and markets AlloFuse® Cortical Fibers and AlloFuse® Fiber Boats; TheraCell also produces private label products to be marketed by other orthopedic companies.
The full offering of procedure-specific fiber grafts is available in the U.S. directly through TheraCell, and will soon be available in Australia and New Zealand.
While the grafts distributed to date by TheraCell’s licensees consist only of the original base fiber products, TheraCell has also launched an expanded portfolio of unique TheraFuze DBF® graft forms, including the DBF Fiber Anchorâ„¢ for immediate enhanced screw fixation, DBF Fiber Bulletsâ„¢ for delivery through a cannula in MIS cases, the DBF Fiber Wrapâ„¢ and the DBF Fiber Bagâ„¢ for graft containment, and a 3-level DBF Fiber Boatâ„¢.
“The success our licensees are having is clear validation of our DBF technology. It provides a solid foundation as we continue to develop advanced bone graft solutions to facilitate surgical procedures.” – Nelson Scarborough, Ph.D., CSO and co-inventor of TheraCell’s DBF Bone Textileâ„¢ technology platform
Over 25,000 of TheraCell's licensed demineralized bone fiber products have been delivered by its licensee partners, to date. These partners have notched steady double-digit quarter over quarter growth, now representing an annual end customer sales rate approaching $30 million.
Licensees of the base fiber technology include AlloSource, which...
Over 25,000 of TheraCell’s licensed demineralized bone fiber products have been delivered by its licensee partners, to date. These partners have notched steady double-digit quarter over quarter growth, now representing an annual end customer sales rate approaching $30 million.
Licensees of the base fiber technology include AlloSource, which produces and markets AlloFuse® Cortical Fibers and AlloFuse® Fiber Boats; TheraCell also produces private label products to be marketed by other orthopedic companies.
The full offering of procedure-specific fiber grafts is available in the U.S. directly through TheraCell, and will soon be available in Australia and New Zealand.
While the grafts distributed to date by TheraCell’s licensees consist only of the original base fiber products, TheraCell has also launched an expanded portfolio of unique TheraFuze DBF® graft forms, including the DBF Fiber Anchorâ„¢ for immediate enhanced screw fixation, DBF Fiber Bulletsâ„¢ for delivery through a cannula in MIS cases, the DBF Fiber Wrapâ„¢ and the DBF Fiber Bagâ„¢ for graft containment, and a 3-level DBF Fiber Boatâ„¢.
“The success our licensees are having is clear validation of our DBF technology. It provides a solid foundation as we continue to develop advanced bone graft solutions to facilitate surgical procedures.” – Nelson Scarborough, Ph.D., CSO and co-inventor of TheraCell’s DBF Bone Textileâ„¢ technology platform
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.